Business Context and Reporting Period
This Form 6-K filing by Autolus Therapeutics Plc covers the month of January 2022, with the report dated January 11, 2022. The filing serves to disclose material corporate governance changes regarding the company's executive leadership.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial statements or performance data.
Material Changes
- Retirement of CFO: Andrew J. Oakley will retire as Chief Financial Officer effective March 31, 2022, to focus on non-executive director roles. The company states this retirement is not related to any disagreement regarding operations, policies, or practices.
- Succession Plan: Mr. Oakley will remain a senior advisor to the company until March 2023.
- Appointment of New CFO: Dr. Lucinda Crabtree has been appointed as the new Chief Financial Officer, effective March 31, 2022.
Guidance, Outlook, and Risks
The filing does not provide financial guidance, outlook, or management commentary on business performance. No specific risks, contingencies, or unusual items are disclosed in this document beyond the standard transition of executive leadership.
Key Facts for Investor Verification
- Verify the effective date of the CFO transition (March 31, 2022) and the interim advisory role of the outgoing CFO.
- Confirm the professional background and qualifications of the incoming CFO, Dr. Lucinda Crabtree, via the referenced press release (Exhibit 99.1).
- Note that this filing incorporates by reference into existing registration statements (Forms F-3 and S-8).